Given that you clicked on this article, it seems safe to assume you either own stock in City National Corp. (NYSE: CYN ) or are considering buying shares in the near future. If so, then you've come to the right place. The table below reveals the nine most critical numbers that investors need to know about City National stock before deciding whether to buy, sell, or hold it.
But before getting to that, a brief introduction is in order. While City National could easily be lumped together with regional banks, it more closely resembles a large community bank and trust with satellite offices in strategic cities throughout the country, including Las Vegas, New York City, Nashville, and Atlanta. Founded by a "small group of entrepreneurs in 1954," the bank is headquartered in Los Angeles and is loosely known as the banker to the stars given its past support of Frank Sinatra, Arnold Schwarzenegger, and others, and the fact that about one-fifth of its business loans are entertainment-related. Its balance sheet boasts $29 billion in assets and it oversees an additional $57 billion in assets under management or administration.
Top 5 Companies To Invest In 2015: Stein Mart Inc.(SMRT)
Stein Mart, Inc. operates retail stores that offer fashion merchandise for women and men in the United States. The company?s stores provide fashion apparel, accessories, shoes, and home fashions. As of April 19, 2011, it operated a chain of 263 retail stores. The company was founded in 1908 and is headquartered in Jacksonville, Florida.
Advisors' Opinion:- [By Reuters]
Joshua Lott/Getty Images NEW YORK -- Several major U.S. retailers posted disappointing sales for November after cautious shoppers pinched their pennies at the start of a shorter holiday season. Some of the companies that reported sales gains ramped up bargains to bring in shoppers who appeared hesitant to splurge. Costco Wholesale (COST) said Thursday that sales at stores open at least a year rose 2 percent, below the 3.3 percent increase analysts were looking for, according to Thomson Reuters. The warehouse club chain said consumer electronics sales fell. Same-store sales at L Brands (LTD), owner of the Victoria's Secret lingerie chain, also came in below expectations. Its drop of 5.5 percent was far deeper than the 1.1 percent decline analysts were projecting. Wall Street analysts are expecting 11 top retailers to report a 2.7 percent increase in same-store sales for November, according to Thomson Reuters. Excluding drugstore operators, which get two-thirds of revenue from prescriptions, that gain is estimated at 2.3 percent. Gap (GPS) will report its November sales after U.S. markets close. Retailers have been contending with low consumer confidence and the need to prod shoppers with bargains this holiday season, which has six fewer days because of a late Thanksgiving. The National Retail Federation on Sunday said U.S. shoppers had spent 2.9 percent less this year over the Thanksgiving weekend, the kickoff to the holiday season. The Conference Board, an industry group, said last week that U.S. consumer confidence fell in November after a sharp drop in October as Americans worried about their future jobs and earnings prospects. Earlier this week, J.C. Penney (JCP) reported a 10.1 percent comparable sales increase, partially reversing a disastrous decline in 2012, but the department store chain had to resort to aggressive bargains. The "environment will remain as competitive" through the holiday season, Chief Executive Officer Myron Ullman said. I
- [By John Udovich]
As we head into Black Friday and the holiday shopping season, small cap apparel retail stocks Cache, Inc (NASDAQ: CACH), Stein Mart, Inc (NASDAQ: SMRT), Pacific Sunwear of California, Inc (NASDAQ: PSUN) and Destination XL Group Inc (NASDAQ: DXLG) have the distinction of being the best performing small cap apparel retail stocks for this year (according to Finviz.com) with gains of 111.6%, 92.7%, 88.7% and 65.7%, respectively. What are these high flying small caps doing right in the apparel retail space and will they continue delivering a stellar performance for Black Friday and the all important holiday season for�investors? Here is what new and existing investors and traders alike need to know or consider:
5 Best Regional Bank Stocks To Invest In Right Now: Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.
In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.
Advisors' Opinion:- [By Sean Williams]
The next big thing in treating hepatitis-C
The other currently experimental therapy very likely to make it onto the FDA's desk before the midpoint of 2014 is AbbVie's (NYSE: ABBV ) direct-acting antiviral combo drug. In similar fashion to Sovaldi, this DAA-combo therapy, which includes ABT-450 from Enanta Pharmaceuticals (NASDAQ: ENTA ) , is running six confirmatory late-stage trials on various genotypes. There are, however, two primary differences between AbbVie's DAA-combo therapy and Sovaldi. - [By James Fink]
And lastly I'll go into healthcare, which is kind of a growth cyclical type name. It's partially defensive, partially growth. I think the more growth-oriented section of healthcare would be biotech, and right now, a very promising biotech stock is Enanta Pharmaceuticals. That's a NASDAQ stock; ticker symbol (ENTA).
- [By George Budwell]
Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE: ABBV ) , Enanta Pharmaceuticals (NASDAQ: ENTA ) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market.�
5 Best Regional Bank Stocks To Invest In Right Now: Gem International Resources Inc (GI)
Gem International Resources Inc. (Gem International) is a Canada-based junior natural resource company. The Company is primarily engaged in the acquisition, exploration and development of mineral properties with its principal focus on diamond, gold and other precious metals. The Company is in exploration-stage and has interest in mineral properties located in Canada and Tanzania. The Company owns more than 105 mining claims comprised of approximately 240,172 acres located in the Lac de Gras Property located approximately 260 kilometers northeast of Yellowknife, Northwest Territories. Its Kolandoto Diamond Property is located in the Shinyanga region of Tanzania. Kolandoto property consists of approximately10 primary mining licenses covering a total area of approximately 247 acres. The Shinyanga Property consists of more than 105 primary mining licenses covering a total area of approximately 2,743 acres. Advisors' Opinion:- [By Victor Selva]
In January 2014, Forest acquired Toronto-based Aptalis, a privately held U.S.-based specialty Gastrointestinal (GI) and Cystic Fibrosis Company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm. The deal looks attractive especially keeping in mind the fact that Namenda will be facing generic competition from 2015. The acquisition will also give Forest the opportunity to build its presence in Europe and strengthen its GI and CF portfolios.
5 Best Regional Bank Stocks To Invest In Right Now: Xerium Technologies Inc.(XRM)
Xerium Technologies, Inc. manufactures and supplies consumable products used in the production of paper clothing and roll covers primarily in North America, Europe, South America, and the Asia-Pacific. It operates in two segments, Clothing and Roll Covers. The Clothing segment provides various types of industrial textiles used on paper-making machines and other industrial applications. This segment offers forming fabrics, press felts, and dryer fabrics; and fabrics used in other industrial applications, such as pulp, steel, plastics, leather, and textiles manufacturing. The Roll Covers segment manufactures, refurbishes, and replaces roll covers for working rolls, including vacuum rolls and press rolls; calendar rolls; and coater rolls that are used on paper-making machines. This segment also refurbishes previously installed roll covers; provides mechanical maintenance and repair services for the internal mechanisms of rolls used on paper-making machines; and manufactures a nd repairs spreader rolls. The company markets its products through its direct sales force under Huyck Wangner, Weavexx, Stowe Woodward, Mount Hope, Robec, and Xibe brand names. Xerium Technologies, Inc. was founded in 1999 and is headquartered in Raleigh, North Carolina.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Xerium Technologies (NYSE: XRM ) , whose recent revenue and earnings are plotted below. - [By Roberto Pedone]
One cyclical consumer goods player that's starting to trend within range of triggering a near-term breakout trade is Xerium Technologies (XRM), a manufacturer and supplier of two types of consumable products, clothing and roll covers, used mainly in the production of paper. This stock has been on fire so far in 2013, with shares up sharply by 313%.
If you take a look at the chart for Xerium Technologies, you'll notice that this stock has been uptrending strong for the last two months and change, with shares moving higher from its low of $9.94 to its recent high of $12.97 a share. During that uptrend, shares of XRM have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of XRM within range of triggering a near-term breakout trade.
Traders should now look for long-biased trades in XRM if it manages to break out above some near-term overhead resistance at $12.97 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 100,685 shares. If that breakout triggers soon, then XRM will set up to re-test or possibly take out its 52-week high at $14.04 a share. Any high-volume move above that level will then give XRM a chance to tag its next major overhead resistance levels at $18 to $20 a share.
Traders can look to buy XRM off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12.28, or near its 50-day at $11.35 a share. One can also buy XRM off strength once it takes out $12.97 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
No comments:
Post a Comment